IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
Rhea-AI Summary
IMUNON (Nasdaq: IMNN) reported final Phase 2 OVATION 2 results showing an improved median overall survival (OS) benefit for IMNN-001 plus standard chemotherapy: a 14.7-month OS increase (45.1 vs. 30.4 months) versus SoC alone. Women receiving IMNN-001 plus PARP inhibitor maintenance showed a 24.2-month OS increase (65.6 vs. 41.4 months).
OVATION 2 randomized 112 patients. IMUNON says Phase 3 OVATION 3 enrollment is ahead of plan, currently open at seven sites with up to 43 sites considered and ~80 patients (~20% of 500 target) expected within a year; two interim OS analyses are planned.
Positive
- Median OS +14.7 months (45.1 vs. 30.4 months)
- PARP subgroup OS +24.2 months (65.6 vs. 41.4 months)
- Phase 3 enrollment ahead; ~80 patients (~20%) expected in next year
- Two planned interim analyses in OVATION 3 enable accelerated BLA timeline
- Favorable safety and tolerability profile maintained
Negative
- Phase 2 size was 112 randomized patients
- OVATION 3 currently at 7 sites; up to 43 additional sites under consideration
News Market Reaction – IMNN
On the day this news was published, IMNN declined 5.44%, reflecting a notable negative market reaction. Argus tracked a peak move of +14.1% during that session. Argus tracked a trough of -27.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $525K from the company's valuation, bringing the market cap to $9.12M at that time. Trading volume was exceptionally heavy at 57.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMNN was down 1.34% while momentum peer BCTX appeared up 9.76%. Broader peers in Biotechnology show mixed moves (e.g., CARM +10%, PRTG -10.39%), suggesting today’s setup looks stock-specific rather than a coordinated sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Trial focus update | Neutral | -1.6% | Reorganization to cut costs and prioritize OVATION 3 Phase 3 trial. |
| Nov 10 | R&D data update | Positive | -6.3% | R&D Day highlighting 13‑month OS benefit and clinical progress. |
| Nov 07 | R&D Day preview | Neutral | +1.0% | Announcement of upcoming R&D Day on OVATION 2/3 and MRD data. |
| Sep 22 | Translational data | Positive | +3.4% | Phase 2 translational data showing TME shift and safety profile. |
| Jul 30 | Phase 3 first dose | Positive | -3.1% | First patient dosed in pivotal Phase 3 OVATION 3 trial. |
Clinical-trial news for IMNN has often produced modest or negative next-day moves, with an average -1.3% reaction and several positive updates met by selling pressure.
Over the past months, IMUNON has repeatedly highlighted clinical progress for IMNN-001 in advanced ovarian cancer, including Phase 2 OVATION 2 data showing a 13‑month median OS benefit and tumor micro‑environment shifts, and initiation plus early enrollment of the pivotal Phase 3 OVATION 3 study. Multiple R&D events and trial milestones carried generally positive scientific tone, yet same‑tag clinical news averaged a -1.3% move, underscoring a pattern of cautious market reactions to otherwise constructive updates.
Historical Comparison
Clinical-trial headlines for IMNN have averaged a -1.3% next-day move. Today’s updated OVATION 2 survival data fit a pattern where constructive trial news has not reliably driven sustained upside.
Same-tag history shows progression from Phase 2 OVATION 2 results and translational TME data through activation, first dosing, and enrollment momentum in the pivotal Phase 3 OVATION 3 study for IMNN-001.
Market Pulse Summary
The stock moved -5.4% in the session following this news. A negative reaction despite the extended survival data would fit a pattern where clinical-trial news averaged a -1.3% move. Even with a 14.7‑month median OS improvement and a 24.2‑month gain in the PARP subgroup, investors have previously sold into positive updates. Ongoing Phase 3 execution across a planned 500‑patient trial and funding needs tied to the program could remain overhangs that shape downside responses.
Key Terms
median overall survival medical
parp inhibitor medical
neoadjuvant medical
adjuvant medical
cytokine medical
interleukin 12 (il-12) medical
biologics license application (bla) regulatory
u.s. food and drug administration (fda) regulatory
AI-generated analysis. Not financial advice.
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis
Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months
Enrollment in IMUNON’s Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community
LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT). The large randomized 112-patient study evaluated IMNN-001 in women with newly diagnosed advanced ovarian cancer. IMNN-001, the company’s lead drug candidate, utilizes its proprietary non-viral DNA delivery platform, TheraPlas®, the only nucleic acid nanoparticle technology showing promise in treating cancer. This novel immunotherapy is designed to recruit the entirety of the immune system by enabling locoregional secretion of the powerful cancer-fighting cytokine interleukin 12 (IL-12), altering the tumor microenvironment.
Based on prior data assessments, IMUNON previously reported a median 11.1-month increase in OS (40.5 vs. 29.4 months) in the IMNN-001 treatment arm compared to SoC chemotherapy alone. Following the most recent data assessment, the company is now reporting a median 14.7-month increase in OS (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC alone, demonstrating continuous improvement in OS (3.6 delta). In addition, the new IMNN-001 data showed that women treated with IMNN-001 and SoC chemotherapy plus poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy achieved a median increase in OS of 24.2 months (65.6 vs. 41.4 months) compared to SoC chemotherapy alone.
“It is very encouraging to see results from the OVATION 2 trial indicating that treatment with IMNN-001 was associated with an overall survival benefit of more than a year in patients treated with IMNN-001 plus chemotherapy and more than two years in women also receiving PARP inhibitors as part of maintenance therapy. These new findings are especially exciting given that there have been no meaningful advances in standard of care in ovarian cancer in the last 30 years,” said Premal H. Thaker, M.D., Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine, OVATION 2 Study Chair and Study Chair of Phase 3 OVATION 3 trial. “Importantly, with these new efficacy results, IMNN-001 continues to maintain a highly favorable safety and tolerability profile, further reinforcing the potential of this IL-12 immunotherapy to represent a landmark advance in treatment for women who are in desperate need of new and improved treatment options.”
“With each new assessment of the findings from the OVATION 2 study, IMNN-001 has continued to show that it can improve overall survival in women with newly diagnosed advanced ovarian cancer while maintaining an advantageous safety profile,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The strong response from our current trial investigators and the broader medical community supports our belief in the significant potential of IMNN-001 to make a meaningful difference in women’s lives. We remain focused on executing our Phase 3 trial and advancing this promising therapy to the final stage of regulatory review as quickly as possible.”
The pivotal Phase 3 OVATION 3 trial is a robustly designed clinical study with the primary endpoint of OS. The trial design includes two planned interim analyses of the primary endpoint, designed to allow for an accelerated timeline for potential submission of a Biologics License Application (BLA) for full approval of IMNN-001 to the U.S. Food and Drug Administration (FDA) if the primary endpoint reaches statistical significance. OVATION 3 is currently enrolling patients at seven clinical sites with up to 43 additional sites being considered for activation. IMUNON anticipates enrolling approximately 80 patients (~
About the Phase 2 OVATION 2 Study
OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2 in addition to N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response.
About IMNN-001 Immunotherapy
Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.
About Epithelial Ovarian Cancer
Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this letter are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
| Contacts: | |
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
What did IMUNON (IMNN) report for median overall survival in Phase 2 OVATION 2 on March 25, 2026?
How much did PARP inhibitors add to OS for IMNN-001 patients in the OVATION 2 trial (IMNN)?
What is the status and enrollment plan for IMUNON's Phase 3 OVATION 3 (IMNN)?
Does IMUNON report safety concerns for IMNN-001 in the OVATION 2 data (IMNN)?
What regulatory path does IMUNON plan for IMNN-001 after OVATION 3 (IMNN)?
How should investors interpret the OVATION 2 results for IMUNON (IMNN) near term?
